Aug 28, 2019 / 06:30AM GMT
Per Walday - PCI Biotech Holding ASA - CEO
Good morning, everyone, and welcome to our PCI Biotech's Second Quarter and First Half 2019 Report Webcast. My name is Per Walday, I'm the CEO of PCI Biotech. I have with me also Ronny Skuggedal who is the CFO, and we have in the audience also the Chairman of the Board, Hans Peter Bøhn.
We will begin with the highlights for the first half 2019 and then follow that by a closer look at our 3 different development programs and after that an overview of financial figures and outlook for the coming year. After that, we will open up for questions from the room as well as questions submitted in through the web link.
So let's start with the highlights for first half 2019. fimaCHEM, our lead program, the first patient was enrolled into the RELEASE study in the first half. We have had regulatory and ethic approvals for the RELEASE study progressing very well, achieved in 2/3 of the planned countries that we will have totally in this is study including the United States. We have also now almost half of the RELEASE study sites opened and actively screening
Half Year 2019 PCI Biotech Holding ASA Earnings Call Transcript
Aug 28, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers